Sandoz, a global market leader, has proven that biosimilars can create expanded patient access while increasing healthcare savings1,3,7,8
Net extrapolated cost savings with biosimilars
in the filgrastim market
Based on year-to-date sales as of March 2019; based on filgrastim net sales of $926 million.
Estimated refers to the extrapolation of the estimated spend based on the assumption that there are no biosimilars in the market.
ASP=average sales price; G-CSF=granulocyte colony-stimulating factor; IDN=integrated delivery network.
Neupogen is a registered trademark of Amgen Inc.
Granix is a registered trademark of Teva Pharmaceutical Industries Ltd.
Nivestym is a registered trademark of Pfizer Inc.
References: 1. FDA approves first biosimilar product Zarxio [press release]. US Food and Drug Administration; March 6, 2015. Accessed August 9, 2019. 2. Data on file. Filgrastim Net Sales Analysis Model. Sandoz Inc. July 2019. 3. Wang W, Campbell K, Balu S. Cost-minimization analysis for biosimilar pegfilgrastim in the prophylaxis of chemotherapy induced (febrile) neutropenia and expanded access based on budget neutral basis. J Clin Oncol. 2019;37(suppl 15):6645. doi:10.1200/JCO.2019.37.15_suppl.6645. 4. US Food and Drug Administration. Presented at: FDA Oncologic Drugs Advisory Committee Meeting; January 7, 2015. 5. Data on file. Novartis Manufacturing Manual Version 2.0. Sandoz Inc. 6. Puckrein G, Xu Liu, Ryan A, Campbell K, Balu S. Potential Medicare beneficiary out-of-pocket reductions through using biosimilar filgrastim-sndz over reference filgrastim: a simulation analysis. Poster presented at: AMCP Nexus; October 22-25, 2018; Orlando, Florida. 7. Data on file. Periodic Safety Update Report (PSUR) 11. Sandoz International GmbH. November 2017. 8. Data on file. Zarxio Global Presence 2018. Sandoz Inc. October 2018. 9. Data on file. Zarxio Market Share Analysis. Sandoz Inc. January 2019. 10. Data on file. Sandoz ZARXIO Wholesale Acquisition Cost (WAC) Data June 2018 Resource. Sandoz Inc. June 2018. 11. Leber MB, Abdelghany O, Miller L. Biosimilar adoption: health system challenges and strategies for success. Poster presented at: 2016 Vizient Clinical Connections Summit; September 28-30, 2016; Dallas, Texas. 12. Data on file. RWJBH Raw Sales Data. Sandoz Inc. March 2018. 13. Data on file. Sandoz 2017 Kaiser Savings Data. Sandoz Inc. June 2018. 14. Trautman H, Szabo E, James E, Tang B. Patient-administered biologic and biosimilar filgrastim may offer more affordable options for patients with nonmyeloid malignancies receiving chemotherapy in the United States: a budget impact analysis from the payer perspective [published online ahead of print August 6, 2018]. J Manag Care Spec Pharm. 2018;1-9. doi:10.18553/jmcp.2018.18094. 15. Data on file. IDN Qualitative Insights Series Presentation created by Zitter Health Insights. Sandoz Inc. 2018. 16. Data on file. Zitter Raw Data. October 2017. 17. Data on file. State-of-the-art manufacturing and quality. Sandoz Inc. 18. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91(3):405-417.